Programme De Prévention Et De Gestion Des Maladies Cardiovasculaires

Objectives

Morocco’s 2018–2021 cardiovascular health programme seeks to reduce avoidable mortality, disability, impaired quality of life and socioeconomic burden from cardiovascular and cerebrovascular diseases, which are the country’s leading cause of death.[1][2]It covers cardiovascular determinants and risk factors, heart and vascular diseases, cerebrovascular disease including stroke, and care from prevention through advanced, geriatric and terminal stages.[1][3]

The programme adopts an integrated, whole-pathway policy rather than separate disease-specific initiatives, linking population prevention, early detection and risk stratification, acute and emergency care, chronic follow-up, rehabilitation, palliative care and support for older people.[4][5][6]Its three strategic orientations are to prevent and reduce cardiovascular risks, manage emergencies and acute episodes, and coordinate care for people with established cardiovascular disease or high and very high cardiovascular risk.[7]

• Reduce the prevalence of high cardiovascular risk in the general population by 25% by 2025.[7]
• Reduce smoking prevalence among young people and the general population by 15% by 2025, alongside a 5% reduction in insufficient physical activity and an approximately 15% reduction in salt consumption.[7][8]
• Reduce acute rheumatic fever incidence by 50% by 2025 through systematic detection and treatment of bacterial sore throat in children.[8]
• Expand validated cardiovascular-risk assessment to 50% of general practice and primary-care patients aged over 45 by 2025.[8]
• Halve one-month mortality from acute cardio-neurovascular events among people under 70 by 2025 and reduce major cardiovascular events and mortality among high-risk patients.[8][9]
• Ensure that 75% of high-risk patients receive a compliant medical and educational follow-up plan by 2025, while extending personalised care plans for fragile and diagnosed patients.[10][11]

Priority action addresses modifiable risks including tobacco use, unhealthy diet, physical inactivity, hypertension, dyslipidaemia, diabetes, abdominal obesity, harmful alcohol use, air pollution and psychosocial stress.[12]Prevention combines healthy-lifestyle promotion, patient and family education, tobacco control, healthier food environments, physical-activity promotion, salt reduction and intersectoral action involving education, transport, urban planning and food-sector stakeholders.[13][14]

The programme also seeks to strengthen primary health care and family medicine as the entry point for cardiovascular prevention and long-term management, while improving access to specialised cardiology, neurovascular, revascularisation, rehabilitation, geriatric and palliative-care services.[15][16]It recognises territorial inequalities in workforce and specialist provision, as well as medicine, equipment, diagnostic and hospital-capacity constraints, as major barriers to equitable cardiovascular care.[17][18]

Implementation

Implementation combines population-based prevention with risk-based clinical management, using integrated primary-care pathways, coordinated referral systems and progressively strengthened emergency and specialist services.[1][19]The Ministry of Health leads the programme, developed with World Health Organization technical support through evidence review, field visits, professional interviews, workshops and consultations involving health services, patients, insurers, learned societies, regional bodies and civil society.[1][20][5]

• Deliver cardiovascular-risk assessment in primary health care and general practice using validated scores based on age, sex, smoking, systolic blood pressure and cholesterol, with treatment and follow-up adjusted to overall risk.[19]
• Implement integrated care for hypertension, cholesterol and diabetes through clinical algorithms, planned consultations, therapeutic education, patient self-management support and access to essential medicines, including low-dose aspirin and statins.[21][9]
• Equip primary-care facilities with blood-pressure monitors, blood-glucose and glycated-haemoglobin devices, electrocardiography, laboratory capacity, electronic records and linked information systems.[21][22]
• Strengthen emergency pathways through public awareness of myocardial infarction and stroke symptoms, improved pre-hospital transport, local coronary thrombolysis, electrocardiogram transmission, coronary angioplasty, stroke imaging, thrombolysis and thrombectomy.[23][24][25]
• Organise four principal pathways for ischaemic heart disease, neurovascular disease including stroke, rheumatic valvular disease and heart failure, with coordinated prevention, acute care, rehabilitation and chronic follow-up.[10][26]
• Develop comprehensive care for frail, older and advanced-disease patients through home follow-up, rehabilitation, geriatric services, palliative care, family involvement and multidisciplinary support.[27][28]

Delivery is intended to begin through pilots, including pilot regions for high-risk management, acute stroke services, rehabilitation and coordinated pathway models, before national extension through regional health organisation plans.[29][30][26]Regional directorates, university and regional hospitals, primary-care teams, professional societies, universities, emergency services, health insurers, civil society and private providers are expected to contribute.[24][31][32]

Governance includes a programme team within the Ministry of Health, an intersectoral steering committee involving ministry directorates, insurers, other ministries, partners and learned societies, and consultation with the Committee on Cardiovascular Diseases.[32][33]Government-level coordination is intended for actions requiring cross-ministerial leadership, particularly prevention and tobacco control.[33][34]

Private-sector contracting may address persistent gaps in public cardiovascular and neurovascular provision, particularly for patients covered by the Medical Assistance Regime, but should operate through time-limited agreements under state and health-insurance supervision, with objectives, pricing conditions, access requirements, monitoring and sanctions for non-compliance.[29][35]

Monitoring mechanisms include clinical patient follow-up, activity monitoring in primary-care establishments and hospitals, information systems, patient records, registers, annual roadmaps, dashboards and national reporting on regional implementation.[30][26][32][33]Explicit time-related measures include a three-hour interval from patient alert to thrombolysis for acute myocardial infarction, a 24-hour target for coronary angioplasty among people under 70, and a proposed 24-hour timeframe for specialised stroke diagnosis and treatment.[23][9]

The programme should have dedicated resources and a specific budget, with measures incorporated into budget discussions and potential support from civil society and other partners.[36][34]However, the supplied material does not specify budget amounts, financing allocations, funding gaps or a comprehensive national indicator and reporting framework.[37][32]

Monitoring & Evaluation

The programme combines evidence generation, routine information strengthening, pilot evaluation and governance-based oversight, but its monitoring framework is unevenly specified. Explicit national outcome and service targets are defined for risk reduction, emergency care and follow-up, while reporting cycles, comprehensive surveillance arrangements and a consolidated accountability framework are often not specified.[7][8][10][26]

• Monitor population outcomes against a 25% reduction in high cardiovascular risk and a 15% reduction in smoking prevalence by 2025.[7]
• Track healthy-lifestyle indicators, including a 5% reduction in insufficient physical activity and an approximately 15% reduction in salt consumption by 2025, alongside a 50% reduction in acute rheumatic fever incidence.[8]
• Assess risk-assessment coverage, with an intended target of 50% of general-practice and primary-care patients aged over 45 receiving cardiovascular risk stratification by 2025.[8]
• Measure acute-care performance through time targets, including thrombolysis for acute myocardial infarction within three hours of the patient-triggered alert and coronary angioplasty within 24 hours for people under 70.[23]
• Measure stroke access against a proposed 24-hour timeframe from patient alert to diagnostic and therapeutic care in a specialised centre for people under 70.[9]
• Monitor high-risk follow-up, targeting a compliant medical and educational follow-up plan for 75% of high-risk patients by 2025.[9][11]
• Track personalised care planning, targeting one in two fragile primary-care patients by 2025 and an individualised care-and-pathway plan for 50% of diagnosed patients by 2021.[10][11]

Information-system development is a central implementation mechanism. Proposed arrangements include clinical patient monitoring, activity monitoring in primary-care establishments and hospitals, patient records, registers, integrated first-line information systems and a dedicated cardiovascular patient record.[27][30][26][38]

• Integrate the individualised care-and-pathway-plan indicator into the first-line care information system.[39]
• Strengthen monitoring of non-communicable disease prevention and management through health-programme information systems.[21]
• Use the 2017 national survey of non-communicable disease risk factors, health-service studies, field visits and epidemiological evidence to update the situation analysis and refine implementation.[40][3][41]
• Address incomplete service monitoring because comparable activity data for private hospitals are unavailable.[42][43]

Piloting and evaluation are envisaged before national scale-up for integrated high-risk management, rehabilitation for frail cardiovascular patients and regional pathway models. Quality indicators are to be developed for primary-care implementation of holistic care, although a full national indicator set and evaluation methodology are not specified.[29][30][28]

Accountability and oversight rely on Ministry of Health leadership, a programme team, an intersectoral steering committee, regional coordination, an annual roadmap, dashboard and evaluation mechanism. A national reporting system is planned for regional implementation, and the Committee on Cardiovascular Diseases is to provide an opinion on implementation.[32][33]

• Evaluate public-private partnerships through monitored experiments, defined objectives and pricing conditions, possible sanctions for non-compliance or diversion, and an overall end-of-programme assessment.[35]
• Require strict assessment of private providers’ compliance with agreed acute-care rules, with possible termination of agreements for non-compliance.[25]
• Strengthen controls over public-private conflicts of interest and other selected compliance risks.[44]

Beyond these mechanisms, the document does not specify a universal reporting timetable, a complete surveillance system, named evaluation responsibilities for every intervention, or a single comprehensive accountability framework.[8][26][45]

Costing & Financing

The programme presents prevention and strengthened primary care as economically important responses to the concentration of expenditure on advanced chronic disease, but it does not provide a total programme cost, detailed budget, funding-gap estimate, costing methodology or currency-denominated financing plan.[12][46][5]

• Recognise that households paid 54% of health expenditure directly in 2010, indicating a substantial financial burden.[12]
• Recognise that 50% of compulsory health-insurance expenditure was directed to 3% of affiliates in 2012, highlighting expenditure concentration among people with substantial health needs.[12]
• Prioritise prevention to reduce future financial pressure on social security, national solidarity arrangements and the state.[12]
• Provide a specific budget and dedicated resources for selected programme measures, although no amount or allocation is specified.[36][34]
• Include programme measures in budget discussions and seek favourable Government decisions on the programme budget.[37][32]

Financing approaches include tobacco taxation, potential taxation of industries whose practices are not considered health-supportive, civil-society participation, international funds, and regulated public-private arrangements where public provision is persistently inadequate. The source does not quantify expected revenues, partner contributions or financing gaps.[14][35][47]

• Increase tobacco taxation and use taxation of industries whose practices are not health-supportive to support prevention and care.[14]
• Seek civil-society and partner support for programme implementation, financing, dissemination and public acceptance.[35]
• Ensure continuity of financing for programme actions and involve international funds and other partners.[47]
• Use time-limited, state- and health-insurance-supervised contracts with private providers to address temporary care gaps, subject to inclusive access and pricing conditions.[35]
• Define health-insurance tariffs or care packages for cardiovascular pathway services, including arrangements involving private clinics and patients covered by the Medical Assistance Scheme.[37]

Resource requirements are substantial but not costed. They include workforce recruitment and training, equipment, medicines, laboratory and imaging capacity, telemedicine, information systems, emergency transport, rehabilitation, palliative care and maintenance.[26][34][45]

Several qualitative economic constraints are identified: high costs for thrombolytic medicines, interventional cardiology and revascularisation infrastructure; treatment, specialist, medicine, laboratory and private-care costs reported by patients; and the high cost of chronic, rehabilitation and palliative care. Home-based palliative care is described as more accessible and less costly than hospital care, without a quantified comparison.[24][16][48][49][50]

Medicines are identified as free in primary healthcare, although supply interruptions are reported. The programme also anticipates diversifying funding sources and reducing thrombolytic costs, but does not specify the magnitude, timing or mechanism of these changes.[22][51][52]